Skip to content
Contact
The problem

Antimicrobial resistance

Antimicrobial resistance (AMR) is one of the most significant threats to modern medicine. It occurs when bacteria evolve to become resistant to treatments they were previously sensitive to.

A gloved hand holding a petri dish used for antimicrobial susceptibility testing
The technical challenge

The cost of AMR

It is estimated that by 2050, 10 million people a year could die due to AMR, with a cumulative cost to the global economy of $1 trillion. Even today it is a huge problem, with estimates that in 2025, 1.9 million deaths were directly attributable to AMR, and 8.2 million deaths associated with it.

10 million

people a year could die due to AMR by 2050

$1 trillion

cumulative cost to the global economy

1.9 million

deaths directly attributable to AMR in 2025

8.2 million

deaths associated with AMR in 2025

Source for 2050 figures: O'Neill J. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. London: Review on Antimicrobial Resistance; 2014.

A hand holding several blister packs of antibiotic tablets
Beyond infection

What happens when antibiotics stop working?

AMR does not just affect our ability to treat bacterial diseases, but also our ability to perform common medical procedures. Many treatments, such as surgeries, cancer chemotherapies and organ transplants, rely on our ability to prevent opportunistic bacterial infections.

Without effective antibacterials, these procedures are much more dangerous, or impossible.

As resistance spreads globally, the development pipeline struggles to keep pace, as many of the antimicrobials that are easiest to find and manufacture have already been developed.

The commercial challenge

The economics of AMR

Despite the urgent clinical need, the commercial environment for developing new antimicrobials is uniquely challenging.

$1.2 billion

The average cost of R&D and clinical trials needed to develop a new antibiotic.

20 years

The time it can take to bring a new antibiotic through development.

$100 million

Sales of new antibiotics are typically $100 million or less. Many companies therefore find it commercially unsustainable to develop new antimicrobials.

Stewardship

Despite this expense, new antibiotics are subject to stewardship programmes, meaning they are typically only used for patients when existing antimicrobials fail. This is essential to preserve the effectiveness of novel agents and slow the emergence of resistance. While beneficial from a public health perspective, it also significantly limits sales volumes and revenue for developers.

Our approach

Rethinking antimicrobial development

At NexaBiome Life Sciences, we are addressing both the technical and commercial issues with developing new antimicrobials by:

  1. Targeting an urgent unmet need.

  2. Developing products in a way that gets to market faster and for less money.

  3. Developing products that address bacterial resistance and enable a viable, sustainable business model.

Next: the solution

Harnessing the potential of phages

Bacteriophages naturally infect and kill bacteria, offering a different approach to tackling bacterial infections.

Explore the potential of phages